Drug intelligence / Profile preview

SVG104

Development stage: Preclinical
Lead developer: SoVarGen
Modality: Gene Therapies
Administration: Intrathecal

Overview

SVG104 is an investigational gene therapy being developed by SoVarGen for the treatment of mild malformation of cortical development with oligodendroglial hyperplasia and epilepsy (MOGHE). MOGHE is a rare, drug-resistant focal epilepsy characterized by somatic mosaicism in the SLC35A2 gene, which encodes a UDP-galactose transporter. SVG104 is designed as a gene replacement therapy to deliver a functional copy of the SLC35A2 gene to the central nervous system, restoring proper UDP-galactose transport and glycosylation pathways, thereby addressing the underlying genetic cause of the disorder and reducing seizure frequency. The program is currently in the discovery stage.

Targets

SLC superfamily (Solute carrier superfamily)

Beyond the preview

Go deeper on SVG104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SVG104.

Explore the full profile